Clinical Trials Logo

MGMT-Unmethylated Glioblastoma clinical trials

View clinical trials related to MGMT-Unmethylated Glioblastoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05694416 Not yet recruiting - Clinical trials for MGMT-Unmethylated Glioblastoma

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.